Business Wire

ECRON-ACUNOVA

Share
Erik Carp appointed Leader Nordic Region at Ecron Acunova A/S, Denmark

Anders Malm, Managing Director of Ecron Acunova and responsible for operations in Europe and North America is pleased to announce that Erik Carp has joined Ecron Acunova as Leader Nordic Region.

Erik Carp joined Ecron Acunova in November with responsibility for the Nordic Region. He will bring much operational experience from local and multinational clinical trials within different therapeutic areas. With a Master in pharmacy from Copenhagen University and a Bachelor in business administration from Copenhagen Business School, Erik Carp brings about 25 years of international clinical operations and business experience from pharmaceutical and biotech companies to Ecron Acunova.

Ecron Acunova (www.ecronacunova.com ) is an expert CRO with over 25 years of track record covering 19 European countries, 9 Asian countries and the United States and Canada. It offers full service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, medical writing, PK/PD services and central laboratory services to pharma, biotech, medical device, nutrition and diagnostic companies. Ecron Acunova operates each region as a priority market with European HQ in Frankfurt, Asian HQ in Singapore, and US HQ in Princeton. With a team of over 350 professionals including about 70 MDs and PhDs, Ecron Acunova is reputed to accelerate pharma time‐to‐market cost effectively.

Speaking on the appointment, Anders Malm, CEO Ecron Acunova Europe, said, “Mr. Carp brings extensive experience in clinical research and he has worked with several CROs over the years as a sponsor. With his experience, Erik Carp can contribute to ensuring that Ecron Acunova’s services continue to meet the specific needs of each our sponsors in terms of quality, timing and budgets. We will continue to serve existing clients and build close relations with biotech and pharmaceutical companies for global as well as local services”.

On his appointment, Mr. Carp said, “Ecron Acunova is a CRO with vast experience within many therapeutic areas. With a highly trained staff in three continents Ecron Acunova has a knowledge base which is unique for a CRO of our size. The company has a global reach, while at the same time we can take care of clients on a local and personal basis. The right size matters in this industry and Ecron Acunova can adapt to the size of each of the sponsors we serve. In our organization, each employee can contribute to the success of our sponsors, make a real difference every day, be visible, accountable and constantly strengthen and develop existing and new competencies. It is a pleasure and privilege for me to be part of Ecron Acunova”.

Contact:

Ecron Acunova Europe HQ
Anders Malm
anders.malm@ecronacunova.com
+49 69 6680 300

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release

Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release

Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye